This is a renewal application for a multidisciplinary hematology training program at New York University School of Medicine which has been in existence for over 42 years. The program is designed to provide two- year research opportunities for 5-6 post-doctoral fellows under the guidance of a faculty of 13 mentors. The training faculty consists of academic hematologists and hematopathologists with active laboratories applying basic science methods to the study of hematologic disorders as well as mentors of the basic science departments of NYU School of Medicine. There is abundant interaction among the faculty members within the program as well as with other scientists at this institution. The clinical research at this institution has been recognized by the NIH in its designation as a Comprehensive Cancer Center and an AIDS Center. The program director's research spans both areas. New faculty members have strengthened the basic science orientation of the program. The faculty works with this framework to train physician-scientists for future work in the academic community. A common theme of all the projects is their orientation to human disease.
These aims will be accomplished by training promising candidates in the design, execution and evaluation of experiments so that they may join the ranks of academic physician-scientists in basic as well as translational hematology research.

Public Health Relevance

As the Nation's population is aging, it is becomes even more necessary that we train physician-scientists in hematologic disorders in basic and translational research. The training program at NYU School of Medicine will continue that mission.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
NHLBI Institutional Training Mechanism Review Committee (NITM)
Program Officer
Chang, Henry
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
New York University
Internal Medicine/Medicine
Schools of Medicine
New York
United States
Zip Code
Santori, Fabio R (2015) Nuclear hormone receptors put immunity on sterols. Eur J Immunol 45:2730-41
Santori, Fabio R (2015) The immune system as a self-centered network of lymphocytes. Immunol Lett 166:109-16
Santori, Fabio R; Huang, Pengxiang; van de Pavert, Serge A et al. (2015) Identification of natural RORγ ligands that regulate the development of lymphoid cells. Cell Metab 21:286-97
Su, Wenjuan; Wynne, Joseph; Pinheiro, Elaine M et al. (2015) Rap1 and its effector RIAM are required for lymphocyte trafficking. Blood 126:2695-703
Raetz, Elizabeth A; Morrison, Debra; Romanos-Sirakis, Eleny et al. (2014) A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leu J Pediatr Hematol Oncol 36:458-63
Xing, Weiman; Busino, Luca; Hinds, Thomas R et al. (2013) SCF(FBXL3) ubiquitin ligase targets cryptochromes at their cofactor pocket. Nature 496:64-8
Reavie, Linsey; Buckley, Shannon M; Loizou, Evangelia et al. (2013) Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression. Cancer Cell 23:362-75
Buckley, Shannon M; Aranda-Orgilles, Beatriz; Strikoudis, Alexandros et al. (2012) Regulation of pluripotency and cellular reprogramming by the ubiquitin-proteasome system. Cell Stem Cell 11:783-98
Wu, Lily; Grigoryan, Arsen V; Li, Yunfeng et al. (2012) Specific small molecule inhibitors of Skp2-mediated p27 degradation. Chem Biol 19:1515-24
Busino, Luca; Millman, Scott E; Scotto, Luigi et al. (2012) Fbxw7α- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma. Nat Cell Biol 14:375-85

Showing the most recent 10 out of 23 publications